Keytruda (pembrolizumab) is prescribed to treat melanoma and other conditions by reviving the body’s immune system. Your response to this drug may vary based on your medical history, diagnosis ...

Two phase 3 trials of Merck & Co's Keytruda in metastatic castration-resistant prostate cancer (CRPC) and advanced liver cancer have ended in failure, proving once again that cancer immunotherapy ...

How Does Keytruda Work for RCC? Some cancer cells have what are called checkpoint proteins known as PD-L1 on their cell surface. Some immune cells in our bodies called T cells have proteins on ...

Most people receive Keytruda infusions for up to 2 years. But in some cases, treatment may last longer if there’s evidence that the drug is still effective and the side effects are minimal.

Merck (NYSE:MRK) said it expects its top-selling drug, Keytruda, to be selected by the U.S. government for price setting ...

Merck & Co's KEYNOTE-158 trial of Keytruda has underpinned another FDA approval, this time for the PD-1 inhibitor as a single-agent therapy as a therapy for endometrial cancer with certain genetic ...

Lenvima plus Keytruda with TACE significantly improved progression-free survival in unresectable, non-metastatic hepatocellular carcinoma compared to TACE with placebo. The study reported a median ...

Merck’s (NYSE:MRK) injectable based on an enzyme developed by South Korea-based Alteogen is the company’s answer to the upcoming patent cliff for intravenously delivered Keytruda, which ...

Padcev plus Keytruda shows superior response and survival rates in first-line metastatic urothelial carcinoma treatment compared to chemotherapy. Padcev monotherapy provides clinical benefits in later ...

Trials are designed to demonstrate whether the addition of Actimab-A to either KEYTRUDA ® or OPDIVO ® can result in improved patient outcomes - MDSCs – Myeloid Derived Suppressor Cells in the ...